Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M116Revenue (TTM) $M9.7Net Margin (%)-146.7Altman Z-Score-6.0
Enterprise Value $M68.2EPS (TTM) $-0.2Operating Margin %-148.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.0Pre-tax Margin (%)-146.7Higher ROA y-yN
Price/Book2.910-y EBITDA Growth Rate %-10.5Quick Ratio5.5Cash flow > EarningsN
Price/Sales10.65-y EBITDA Growth Rate %-6.7Current Ratio5.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-29.9Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-41.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M71.1ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARQL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARQLFirst Eagle Investment 2016-03-31 Add0.01%$1.43 - $2.17
($1.76)
$ 1.63-7%Add 24.14%10,825,233
ARQLFirst Eagle Investment 2015-06-30 Add0.01%$1.53 - $2.26
($1.93)
$ 1.63-16%Add 52.45%8,719,968
ARQLFirst Eagle Investment 2015-03-31 Add0.01%$1.1 - $2.46
($1.59)
$ 1.633%Add 28.69%5,719,968
ARQLFirst Eagle Investment 2014-12-31 Add$1.06 - $1.36
($1.18)
$ 1.6338%Add 56.31%4,444,899
ARQLGeorge Soros 2014-09-30 Sold Out $1.12 - $1.56
($1.31)
$ 1.6324%Sold Out0
ARQLGeorge Soros 2014-06-30 Buy $1.34 - $2.04
($1.56)
$ 1.634%New holding78,600
ARQLFirst Eagle Investment 2013-09-30 Reduce-0.01%$2.15 - $2.79
($2.51)
$ 1.63-35%Reduce -26.47%3,314,553
ARQLFirst Eagle Investment 2012-12-31 Add0.01%$2.18 - $2.95
($2.6)
$ 1.63-37%Add 49.46%4,539,651
ARQLFirst Eagle Investment 2012-06-30 Add0.01%$5.53 - $8.16
($6.56)
$ 1.63-75%Add 28.79%2,673,589
ARQLGeorge Soros 2011-12-31 Sold Out -0.0014%$4.58 - $6.05
($5.55)
$ 1.63-71%Sold Out0
ARQLGeorge Soros 2011-09-30 Add$4.11 - $6.64
($5.2)
$ 1.63-69%Add 54.79%16,100
ARQLFirst Eagle Investment 2011-03-31 Add0.03%$5.85 - $6.95
($6.41)
$ 1.63-75%Add 84.22%1,693,456
ARQLGeorge Soros 2011-03-31 Buy $5.85 - $6.95
($6.41)
$ 1.63-75%New holding12,200
ARQLFirst Eagle Investment 2010-12-31 Add0.01%$4.95 - $6.14
($5.53)
$ 1.63-71%Add 29.43%919,266
ARQLFirst Eagle Investment 2010-03-31 Reduce-0.03%$3.04 - $3.92
($3.45)
$ 1.63-53%Reduce -56.47%685,266
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARQL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARQL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LOBERG MICHAEL DDirector 2015-12-17Buy3,719$2.16-24.54view
LOBERG MICHAEL DDirector 2015-12-16Buy1,231$2.14-23.83view
Pucci PaoloCEO 2015-12-15Buy1,283$2.16-24.54view
Pucci PaoloCEO 2015-12-11Buy1,108$2.1-22.38view
ZENNER PATRICK JDirector 2015-12-11Buy2,300$2.15-24.19view
Pucci PaoloCEO 2015-12-10Buy7,609$2.1-22.38view
ZENNER PATRICK JDirector 2015-03-11Buy10,625$2.32-29.74view
Pucci PaoloCEO 2014-11-20Buy5,000$1.2629.37view
ZENNER PATRICK JDirector 2014-11-14Buy20,830$1.235.83view
Messenger William GDirector 2014-11-14Buy8,500$1.2134.71view

Quarterly/Annual Reports about ARQL:

News about ARQL:

Articles On GuruFocus.com
Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc May 05 2015 
Jean-Marie Eveillard Adds to Stake in Arqule Inc. May 03 2015 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 
ArQule Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 Jul 20 2016
ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and... Jul 18 2016
ArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016 Jul 05 2016
Here’s What The ArQule, Inc. (ARQL) Data Really Means Jul 01 2016
ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity... Jun 30 2016
Forget Valeant, Invest in These Attractive Drug Stocks Instead Jun 28 2016
ArQule (ARQL) Shows Strength: Stock Adds 8% in Session Jun 23 2016
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic... Jun 23 2016
ETF’s with exposure to ArQule, Inc. : June 20, 2016 Jun 20 2016
ArQule: Advancing a Deep and Diverse Clinical Stage Pipeline Jun 20 2016
ARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 26 2016
ArQule, Inc. :ARQL-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
ARQULE INC Financials May 10 2016
Edited Transcript of ARQL earnings conference call or presentation 4-May-16 1:00pm GMT May 04 2016
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 04 2016
ArQule reports 1Q loss May 04 2016
ArQule reports 1Q loss May 04 2016
Q1 2016 ArQule Inc Earnings Release - Before Market Open May 04 2016
ArQule Reports First Quarter 2016 Financial Results May 04 2016
ArQule To Report First Quarter 2016 Financial Results On May 4, 2016 May 03 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)